MX2023004733A - Pruebas in vitro y con base en celula para medir la actividad de neurotoxinas botulinicas. - Google Patents
Pruebas in vitro y con base en celula para medir la actividad de neurotoxinas botulinicas.Info
- Publication number
- MX2023004733A MX2023004733A MX2023004733A MX2023004733A MX2023004733A MX 2023004733 A MX2023004733 A MX 2023004733A MX 2023004733 A MX2023004733 A MX 2023004733A MX 2023004733 A MX2023004733 A MX 2023004733A MX 2023004733 A MX2023004733 A MX 2023004733A
- Authority
- MX
- Mexico
- Prior art keywords
- activity
- neurotoxin
- polypeptides
- disclosed
- vitro
- Prior art date
Links
- 108030001720 Bontoxilysin Proteins 0.000 title abstract 3
- 231100001103 botulinum neurotoxin Toxicity 0.000 title abstract 3
- 238000000423 cell based assay Methods 0.000 title 1
- 238000000099 in vitro assay Methods 0.000 title 1
- 239000002581 neurotoxin Substances 0.000 abstract 5
- 231100000618 neurotoxin Toxicity 0.000 abstract 5
- 229920001184 polypeptide Polymers 0.000 abstract 4
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 4
- 101710138657 Neurotoxin Proteins 0.000 abstract 3
- 238000003776 cleavage reaction Methods 0.000 abstract 2
- 230000007017 scission Effects 0.000 abstract 2
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 1
- 108030001722 Tentoxilysin Proteins 0.000 abstract 1
- 210000004900 c-terminal fragment Anatomy 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 238000012512 characterization method Methods 0.000 abstract 1
- 230000007423 decrease Effects 0.000 abstract 1
- 238000001514 detection method Methods 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 210000004898 n-terminal fragment Anatomy 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 230000004952 protein activity Effects 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0069—Oxidoreductases (1.) acting on single donors with incorporation of molecular oxygen, i.e. oxygenases (1.13)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/66—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving luciferase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
- G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
- C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
- G01N2333/33—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Clostridium (G)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
En la presente se describen medios para la detección y caracterización de neurotoxinas como la neurotoxina botulínica (BoNT) o neurotoxina tetánica. La presente descripción proporciona métodos para determinar la potencia y actividad de las neurotoxinas in vitro e in vivo. También se describen polipéptidos que comprenden fragmentos de extremo N y C de una proteína indicadora que se dividen mediante un enlazador que comprende un sitio de escisión de neurotoxina. La escisión del enlazador por una neurotoxina disminuye la actividad de la proteína indicadora, lo que indica la actividad de la neurotoxina. También se describen las composiciones y kits que comprenden los polipéptidos descritos, los ácidos nucleicos que comprenden secuencias de nucleótidos que codifican dichos polipéptidos y las células que expresan dichos polipéptidos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662410558P | 2016-10-20 | 2016-10-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023004733A true MX2023004733A (es) | 2023-05-10 |
Family
ID=60413254
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019004431A MX2019004431A (es) | 2016-10-20 | 2017-10-19 | Pruebas in vitro y con base en celula para medir la actividad de neurotoxinas botulinicas. |
| MX2023004733A MX2023004733A (es) | 2016-10-20 | 2019-04-15 | Pruebas in vitro y con base en celula para medir la actividad de neurotoxinas botulinicas. |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019004431A MX2019004431A (es) | 2016-10-20 | 2017-10-19 | Pruebas in vitro y con base en celula para medir la actividad de neurotoxinas botulinicas. |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US11306347B2 (es) |
| EP (1) | EP3529616B1 (es) |
| JP (2) | JP7227901B2 (es) |
| KR (1) | KR102556363B1 (es) |
| CN (1) | CN110088624B (es) |
| AU (1) | AU2017345560A1 (es) |
| BR (1) | BR112019007831A2 (es) |
| CA (1) | CA3040507A1 (es) |
| DK (1) | DK3529616T5 (es) |
| EA (1) | EA039761B1 (es) |
| ES (1) | ES2963830T3 (es) |
| FI (1) | FI3529616T3 (es) |
| HU (1) | HUE064332T2 (es) |
| MX (2) | MX2019004431A (es) |
| PL (1) | PL3529616T3 (es) |
| PT (1) | PT3529616T (es) |
| SA (1) | SA519401607B1 (es) |
| SG (1) | SG11201903523YA (es) |
| WO (1) | WO2018075783A2 (es) |
| ZA (1) | ZA201902654B (es) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3202903B1 (en) | 2010-12-22 | 2020-02-12 | President and Fellows of Harvard College | Continuous directed evolution |
| US10920208B2 (en) | 2014-10-22 | 2021-02-16 | President And Fellows Of Harvard College | Evolution of proteases |
| WO2016168631A1 (en) | 2015-04-17 | 2016-10-20 | President And Fellows Of Harvard College | Vector-based mutagenesis system |
| US10392674B2 (en) | 2015-07-22 | 2019-08-27 | President And Fellows Of Harvard College | Evolution of site-specific recombinases |
| US11524983B2 (en) | 2015-07-23 | 2022-12-13 | President And Fellows Of Harvard College | Evolution of Bt toxins |
| US10612011B2 (en) | 2015-07-30 | 2020-04-07 | President And Fellows Of Harvard College | Evolution of TALENs |
| IL294014B2 (en) | 2015-10-23 | 2024-07-01 | Harvard College | Nucleobase editors and their uses |
| MX2018014066A (es) * | 2016-05-16 | 2019-04-04 | Harvard College | Metodo para purificacion y activacion de la neurotoxina botulinica. |
| PL3529616T3 (pl) | 2016-10-20 | 2024-03-18 | President And Fellows Of Harvard College | Testy in vitro i komórkowe do pomiaru aktywności neurotoksyn botulinowych |
| US11447809B2 (en) | 2017-07-06 | 2022-09-20 | President And Fellows Of Harvard College | Evolution of tRNA synthetases |
| WO2019040935A1 (en) | 2017-08-25 | 2019-02-28 | President And Fellows Of Harvard College | EVOLUTION OF PEPTIDASES BONT |
| WO2019056002A1 (en) | 2017-09-18 | 2019-03-21 | President And Fellows Of Harvard College | CONTINUOUS EVOLUTION FOR STABILIZED PROTEINS |
| WO2019241649A1 (en) | 2018-06-14 | 2019-12-19 | President And Fellows Of Harvard College | Evolution of cytidine deaminases |
| WO2021011579A1 (en) * | 2019-07-15 | 2021-01-21 | President And Fellows Of Harvard College | Evolved botulinum neurotoxins and uses thereof |
| US20210301319A1 (en) * | 2020-03-26 | 2021-09-30 | Cellex, Inc. | Protease assays and their applications |
| CN114540419A (zh) * | 2022-03-04 | 2022-05-27 | 中国人民解放军军事科学院军事医学研究院 | 一种分析包膜病毒膜融合效率的三功能报告系统 |
| GB202213479D0 (en) | 2022-09-14 | 2022-10-26 | Ipsen Biopharm Ltd | Cell-free clostridial neurotoxin assays |
| GB202404021D0 (en) | 2024-03-20 | 2024-05-01 | Ipsen Biopharm Ltd | Cell-based neurotoxin assay |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4737462A (en) | 1982-10-19 | 1988-04-12 | Cetus Corporation | Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β |
| US4518584A (en) | 1983-04-15 | 1985-05-21 | Cetus Corporation | Human recombinant interleukin-2 muteins |
| US4950588A (en) | 1985-07-10 | 1990-08-21 | Molecular Diagnostics, Inc. | Prolonged enhanced chemiluminescence |
| DE3537877A1 (de) | 1985-10-24 | 1987-04-30 | Geiger Reinhard | Luciferin-derivate und immunoassays unter einsatz derartiger luciferin-derivate |
| US5004565A (en) | 1986-07-17 | 1991-04-02 | The Board Of Governors Of Wayne State University | Method and compositions providing enhanced chemiluminescence from 1,2-dioxetanes |
| US5374534A (en) | 1990-07-19 | 1994-12-20 | Charm Sciences, Inc. | Method of preparing D-luciferin derivatives |
| DE4210759A1 (de) | 1992-04-01 | 1993-10-07 | Boehringer Mannheim Gmbh | Substituierte Thiazolin-Dioxetan-Substrate, Verfahren zur Herstellung und Verwendung |
| JP3523879B2 (ja) | 1994-05-31 | 2004-04-26 | アレルガン インコーポレイテッド | 輸送タンパク質用クロストリジウム属細菌毒素の修飾 |
| GB9508204D0 (en) | 1995-04-21 | 1995-06-07 | Speywood Lab Ltd | A novel agent able to modify peripheral afferent function |
| GB9617671D0 (en) | 1996-08-23 | 1996-10-02 | Microbiological Res Authority | Recombinant toxin fragments |
| GB9721189D0 (en) | 1997-10-08 | 1997-12-03 | Speywood Lab The Limited | Analgesic conjugates |
| DE69938293T2 (de) | 1998-03-27 | 2009-03-12 | Bruce J. Beverly Hills Bryan | Luciferase, gfp fluoreszenzproteine, kodierende nukleinsaüre und ihre verwendung in der diagnose |
| US6890745B1 (en) * | 2000-07-19 | 2005-05-10 | Chemicon International, Inc. | Protease specific cleavable luciferases and methods of use thereof |
| JP2007508014A (ja) * | 2003-10-10 | 2007-04-05 | プロメガ コーポレイション | ルシフェラーゼバイオセンサー |
| US8753831B2 (en) | 2007-06-05 | 2014-06-17 | City Of Hope | Methods for detection of botulinum neurotoxin |
| PL3409764T3 (pl) | 2009-05-01 | 2020-07-13 | Promega Corporation | Syntetyczne lucyferazy z krewetki oplορηorus emitującej bardziej intensywne światło |
| US20140287433A1 (en) * | 2011-07-19 | 2014-09-25 | ETH Zürich | Means and methods for determining clostridial neurotoxins |
| WO2013131991A1 (en) | 2012-03-07 | 2013-09-12 | Merz Pharma Gmbh & Co. Kgaa | Means and methods for determining neurotoxin activity based on a modified luciferase |
| KR102073111B1 (ko) * | 2012-10-16 | 2020-02-04 | 메르츠 파마 게엠베하 운트 코. 카가아 | 신경독소 폴리펩티드의 생물학적 활성의 결정을 위한 세포 테스트 시스템 |
| EP2922866B1 (en) * | 2012-11-21 | 2019-01-23 | Merz Pharma GmbH & Co. KGaA | Means and methods for determination of botulinum neurotoxin biological activity |
| BR112015023394B8 (pt) | 2013-03-15 | 2023-09-26 | Promega Corp | Sistema e complexo bioluminescente |
| RU2704808C2 (ru) * | 2013-06-28 | 2019-10-31 | Мерц Фарма Гмбх Энд Ко. Кгаа | Средства и способы для определения биологической активности полипептидов нейротоксина в клетках |
| EP3274364B1 (en) * | 2015-03-26 | 2021-08-04 | President and Fellows of Harvard College | Engineered botulinum neurotoxin |
| PL3529616T3 (pl) | 2016-10-20 | 2024-03-18 | President And Fellows Of Harvard College | Testy in vitro i komórkowe do pomiaru aktywności neurotoksyn botulinowych |
| SG11202106073QA (en) * | 2018-12-11 | 2021-07-29 | Q32 Bio Inc | Fusion protein constructs for complement associated disease |
-
2017
- 2017-10-19 PL PL17801528.5T patent/PL3529616T3/pl unknown
- 2017-10-19 EP EP17801528.5A patent/EP3529616B1/en active Active
- 2017-10-19 CA CA3040507A patent/CA3040507A1/en active Pending
- 2017-10-19 DK DK17801528.5T patent/DK3529616T5/da active
- 2017-10-19 CN CN201780077166.5A patent/CN110088624B/zh active Active
- 2017-10-19 SG SG11201903523YA patent/SG11201903523YA/en unknown
- 2017-10-19 PT PT178015285T patent/PT3529616T/pt unknown
- 2017-10-19 MX MX2019004431A patent/MX2019004431A/es unknown
- 2017-10-19 FI FIEP17801528.5T patent/FI3529616T3/fi active
- 2017-10-19 BR BR112019007831A patent/BR112019007831A2/pt unknown
- 2017-10-19 KR KR1020197013429A patent/KR102556363B1/ko active IP Right Grant
- 2017-10-19 EA EA201990929A patent/EA039761B1/ru unknown
- 2017-10-19 US US16/343,513 patent/US11306347B2/en active Active
- 2017-10-19 ES ES17801528T patent/ES2963830T3/es active Active
- 2017-10-19 AU AU2017345560A patent/AU2017345560A1/en active Pending
- 2017-10-19 HU HUE17801528A patent/HUE064332T2/hu unknown
- 2017-10-19 JP JP2019521130A patent/JP7227901B2/ja active Active
- 2017-10-19 WO PCT/US2017/057411 patent/WO2018075783A2/en unknown
-
2019
- 2019-04-15 MX MX2023004733A patent/MX2023004733A/es unknown
- 2019-04-18 SA SA519401607A patent/SA519401607B1/ar unknown
- 2019-04-26 ZA ZA2019/02654A patent/ZA201902654B/en unknown
-
2022
- 2022-03-10 US US17/691,848 patent/US11788069B2/en active Active
- 2022-10-21 JP JP2022169039A patent/JP2023011700A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| HUE064332T2 (hu) | 2024-03-28 |
| KR20190068582A (ko) | 2019-06-18 |
| US20220356508A1 (en) | 2022-11-10 |
| EA201990929A1 (ru) | 2019-10-31 |
| DK3529616T3 (da) | 2023-12-11 |
| CA3040507A1 (en) | 2018-04-26 |
| JP7227901B2 (ja) | 2023-02-22 |
| EA039761B1 (ru) | 2022-03-10 |
| SA519401607B1 (ar) | 2022-08-04 |
| JP2023011700A (ja) | 2023-01-24 |
| PT3529616T (pt) | 2023-12-06 |
| US11306347B2 (en) | 2022-04-19 |
| US20190276873A1 (en) | 2019-09-12 |
| JP2019532651A (ja) | 2019-11-14 |
| WO2018075783A2 (en) | 2018-04-26 |
| SG11201903523YA (en) | 2019-05-30 |
| AU2017345560A1 (en) | 2019-05-02 |
| KR102556363B1 (ko) | 2023-07-18 |
| BR112019007831A2 (pt) | 2019-10-01 |
| MX2019004431A (es) | 2019-08-14 |
| CN110088624A (zh) | 2019-08-02 |
| ES2963830T3 (es) | 2024-04-02 |
| CN110088624B (zh) | 2024-01-16 |
| DK3529616T5 (da) | 2024-09-02 |
| WO2018075783A3 (en) | 2018-06-21 |
| PL3529616T3 (pl) | 2024-03-18 |
| US11788069B2 (en) | 2023-10-17 |
| ZA201902654B (en) | 2024-08-28 |
| EP3529616A2 (en) | 2019-08-28 |
| FI3529616T3 (fi) | 2023-12-04 |
| EP3529616B1 (en) | 2023-09-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201902654B (en) | In vitro and cell based assays for measuring the activity of botulinum neurotoxins | |
| MX360513B (es) | Medios y metodos para la determinacion de la actividad biologica de polipeptidos de neurotoxina en celulas. | |
| MX2020005127A (es) | Plataforma de presentacion en endosporas basadas en paenibacillus, productos y metodos relacionados. | |
| PH12016500239A1 (en) | Antibodies to plasminogen activator inhibitor-1 (pai-1) and uses thereof | |
| EP4299760A3 (en) | Probes for improved melt discrimination and multiplexing in nucleic acid assays | |
| BR112017017884A2 (pt) | switches transcricionais desencadeados por ligação e métodos de uso dos mesmos | |
| MX2019009222A (es) | Neurotoxinas recombinantes de clostridium botulinum. | |
| BR112015010550A8 (pt) | Usos de lys-c, métodos para fabricação de um polipeptídeo proteoliticamente processado, para fabricação de um polipeptídeo proteoliticamente ativo, para avaliação para um inibidor do polipeptídeo proteoliticamente ativo, e para geração de fragmentos de polipeptídeo, composições, polipeptídeo proteoliticamente ativo, uso do mesmo, molécula de ácido nucléico, vetor, célula e uso de um polipeptídeo processado | |
| PH12015502849B1 (en) | Biomarkers for cognitive dysfunction diseases and method for detecting cognitive dysfunction disease using biomarkers | |
| NZ733709A (en) | Clostridium histolyticum enzymes and methods for the use thereof | |
| PH12014501970A1 (en) | Antibodies to bradykinin b1 receptor ligands | |
| WO2012009704A3 (en) | Novel peptides and uses thereof | |
| MX2018012550A (es) | Composiciones y metodos para la deteccion de proteinas de celulas huesped. | |
| SG10201807867XA (en) | Simultaneous detection of target protein and target nucleic acids in a single cell | |
| EA201691011A1 (ru) | Последовательность модифицированного эндолизина el188 | |
| EA202190469A1 (ru) | Способы оценки интегрированных нуклеиновых кислот | |
| MX2021013976A (es) | Secuencias de direccionamiento para plataforma de visualizacion de endosporas basada en paenibacillus. | |
| BRPI1006628B8 (pt) | método para produzir uma enzima lipolítica | |
| WO2009090269A3 (en) | Markers and diagnostic methods for metastasis | |
| EA202190892A1 (ru) | Клеточные анализы клостридиальных нейротоксинов | |
| NZ717178A (en) | Expression constructs and methods for expressing polypeptides in eukaryotic cells | |
| MX2015004373A (es) | Moleculas de acidos nucleicos para una mayor produccion de proteinas. | |
| GB201106188D0 (en) | Production of extracellular polypeptides | |
| WO2016022514A3 (en) | Inhibitory rna for enhanced protein production in recombinant mammalian cells | |
| PL413388A1 (pl) | Sposób wykrywania Paecilomyces variotii |